Brief: Travere Therapeutics Q2 EPS USD -0.91 Vs. IBES Estimate USD -0.86
Aug 01 (Reuters) - Travere Therapeutics Q2 operating income USD -67.704 million vs. IBES estimate USD -64.6 million. * Q2 net income USD -70.409 million * Q2 product sales USD 52.176 million vs. IBES estimate USD 50.2 million * Q2 operating expenses USD 121.82 million
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule